A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils)

H L Petsky,1,4 C J Cates,2 T J Lasserson,2 A M Li,3 C Turner,4 J A Kynaston,5 A B Chang1,6

ABSTRACT
Asthma severity and control can be measured both subjectively and objectively. Traditionally asthma treatments have been individualised using symptoms and spirometry/peak flow. Increasingly treatment tailored in accordance with inflammatory markers (sputum eosinophil counts or fractional exhaled nitric oxide (FeNO) data) is advocated as an alternative strategy. The objective of this review was to evaluate the efficacy of tailoring asthma interventions based on inflammatory markers (sputum analysis and FeNO) in comparison with clinical symptoms (with or without spirometry/peak flow) for asthma-related outcomes in children and adults. Cochrane Airways Group Specialised Register of Trials, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and reference lists of articles were searched. The last searches were in February 2009. All randomised controlled comparisons of adjustment of asthma treatment based on sputum analysis or FeNO compared with traditional methods (primarily clinical symptoms and spirometry/peak flow) were selected. Results of searches were reviewed against predetermined criteria for inclusion. Relevant studies were selected, assessed and data extracted independently by at least two people. The trial authors were contacted for further information. Data were analysed as ‘intervention received’ and sensitivity analyses performed. Six (2 adults and 4 children/adolescent) studies utilising FeNO and three adult studies utilising sputum eosinophils were included. These studies had a degree of clinical heterogeneity including definition of asthma exacerbations, duration of study and variations in cut-off levels for percentage of sputum eosinophils and FeNO to alter management in each study. Adults who had treatment adjusted according to sputum eosinophils had a reduced number of exacerbations compared with the control group (52 vs 77 patients with ≥1 exacerbation in the study period; p=0.0006). There was no significant difference in exacerbations between groups for FeNO compared with controls. The daily dose of inhaled corticosteroids at the end of the study was decreased in adults whose treatment was based on FeNO in comparison with the control group (mean difference −450.03 μg, 95% CI −676.73 to −223.34; p<0.0001). However, children who had treatment adjusted according to FeNO had an increase in their mean daily dose of inhaled corticosteroids (mean difference 140.18 μg, 95% CI 28.94 to 251.42; p=0.014). It was concluded that tailoring of asthma treatment based on sputum eosinophils is effective in decreasing asthma exacerbations. However, tailoring of asthma treatment based on FeNO levels has not been shown to be effective in improving asthma outcomes in children and adults. At present, there is insufficient justification to advocate the routine use of either sputum analysis (due to technical expertise required) or FeNO in everyday clinical practice.

INTRODUCTION
Monitoring tools to assist in improving asthma control and prevention of exacerbations are two key elements in asthma guidelines.1–3 There is no single outcome measure that can adequately assess asthma control.4 Subjective measures usually involve a series of questions used for clinical assessment, diary cards and quality of life (QoL) questionnaires. Traditional objective methods used to monitor (but not control) asthma include spirometry/peak flow and degree of airway hyperresponsiveness (AHR).5 Newer methods include measurement of airway inflammation such as airway cellularity in induced sputum or fractional exhaled nitric oxide (FeNO).

The inflammation in airways of people with asthma can be predominantly eosinophilic or non-eosinophilic (including neutrophilic),6 irrespective of the type of airway inflammation, inhaled corticosteroids (ICS) remain the major preventer treatment to control asthma symptoms in those with asthma, other than children with mild intermittent asthma.3 However, ICS are more effective in reducing symptoms in patients with eosinophilic inflammation than those with neutrophilic inflammation.7 Thus investigations that provide objective data on eosinophilic inflammation may be helpful in reducing exacerbations and improve asthma control. Current available techniques for clinical use are assessment of sputum cellularity and FeNO.8

A systematic review evaluating the efficacy of tailoring asthma interventions based on utilising sputum eosinophils or FeNO in comparison with current strategy (reliance on clinical symptoms with or without spirometry/peak flow) will be useful to guide clinical practice. Here we combine two Cochrane reviews9 10 that address this question. The objective of this systematic review is to evaluate the efficacy of tailoring asthma interventions based on FeNO or sputum eosinophils in comparison with controls (clinical symptoms with or without spirometry/peak flow) for asthma-related outcomes in children and adults.
METHODS

Methods of the analysis and inclusion criteria were specified in advance and documented in protocols that are available alongside the original versions of these reviews in The Cochrane Library.

Eligibility, information sources, search strategy and study selection

We used the PRISMA guidelines, Cochrane collaboration methodology and software (RevMan5). We searched the Cochrane Airways Group specialised register for eligible randomised controlled trials that compared adjustment of asthma medications based on sputum eosinophils or FeNO levels in comparison with clinical symptoms (with or without spirometry/peak flow) using keywords in electronic sources (Cochrane Airways Group Specialised Register of Trials, the Cochrane Central Register of Controlled Trials (CENTRAL), Medline, EMBASE) and hand searching of references as outlined in the reviews. The latest searches were performed in February 2009. Trials that included the use of other interventions were included if all participants had equal access to such interventions.

Participant inclusion criteria were children and adults with 'classical asthma'. Exclusion criteria were: eosinophilic bronchitis, asthma related to an underlying lung disease such as bronchiectasis and chronic obstructive airway disease, or diagnostic categories such as 'cough variant asthma' and 'wheezy bronchitis' where controversies exist.

Data items

From the title, abstract or descriptors, the literature search was reviewed independently in triplicate to identify potentially relevant trials for full review. Searches of bibliographies and texts were conducted to identify additional studies. From the full text using specific criteria, two reviewers independently selected trials for inclusion. There was no disagreement, although it was planned that disagreement would have been resolved by third-party adjudication. We extracted information from each trial on (1) study characteristics, (2) intervention type and (3) outcomes, as described in our Cochrane reviews.

Risk of bias

Risk of bias for each study was assessed using the tool available in the RevMan software. Six components were assessed: (1) adequate sequence generation; (2) allocation concealment; (3) blinding; (4) incomplete outcome data addressed; (5) free of selective reporting; and (6) free of other bias. Studies included in the review underwent quality assessment and were entered into a ‘risk of bias’ table.

Summary (outcome) measures

Primary outcomes were the number of participants who had asthma exacerbations during follow-up. Secondary outcomes were mean difference in asthma-related outcome measures, number of participants experiencing adverse effects of the interventions and number of participants experiencing complications such as requirement for medication change. The proportions of participants and the mean clinical improvement were determined using the following hierarchy of assessment measures (ie, where two or more assessment measures are reported in the same study, the outcome measure that is listed first in the hierarchy was used):

1. Hospitalisation, acute presentations to an emergency facility for asthma.
2. Rescue courses of oral corticosteroids.
3. Symptomatic (QoL, Likert scale, asthma diary, visual analogue scale)—assessed by the patient (adult or child).
4. Symptomatic (QoL, Likert scale, asthma diary, visual analogue scale)—assessed by the parents/carers.
5. Symptomatic (Likert scale, visual analogue scale)—assessed by clinicians.
6. Indices of spirometry, peak flow, AHR.
7. β-Agonist used.

In addition, dose of ICS used was also analysed as a post hoc analysis.

Methods of analysis

The results from studies that met the inclusion criteria and reported any of the outcomes of interest were included in the subsequent meta-analyses. All data were double entered (HP and AC) and triple checked (CC). For the dichotomous outcome variables of each individual study, relative and absolute risk reductions were calculated using a modified intention-to-treat analysis when the outcome event is a beneficial event. When the event is non-beneficial (such as exacerbation), ‘treatment received’ analysis was utilised. The summary weighted RR and 95% CI (fixed effect model) were calculated (Cochrane statistical package, RevMan 5.0). For rate ratios of common events whereby one subject may have more than one event, generic
<table>
<thead>
<tr>
<th>Study</th>
<th>Sample size</th>
<th>Participant age</th>
<th>Description of intervention and control arms</th>
<th>Primary outcome and definition of exacerbation</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chilumsky 2006</td>
<td>55 randomised Eosinophil strategy, n=30</td>
<td>Study group: mean age 42 (SD 19), 13 males</td>
<td>Standard strategy arm: treatment decisions were based on morning PEF variation, frequency of daytime symptoms or SABA use/week, frequency of night time symptoms or SABA/week. Eosinophil strategy: treatment decisions were based on the same as the standard strategy arm plus sputum eosinophils as a % of total cell count. All participants scored asthma symptoms in an electronic diary over 30 weeks.</td>
<td>Primary outcome: rate of asthma exacerbations Secondary outcomes: FEV1, postbronchodilator FEV1 and FEV1 inspiratory vital capacity ratio. Exacerbation: a doubling of the frequency of symptoms or number of puffs of rescue salbutamol or a reduction in morning PEF by ≥30% on at least two consecutive days or two of the aforementioned or all three. Primary outcome: proportion of symptom-free days over the last 12 study weeks. Secondary outcomes: cumulative symptom scores, ICS dose as budesonide equivalent, FEV1, and reversibility, FeNO 0.05, prednisone courses, emergency visits, hospitalisations for asthma and PACQLQ scores. Exacerbation: emergency visit, hospitalisation or prednisolone course</td>
<td>Participants were assessed every 3 months for 18 months</td>
</tr>
<tr>
<td>de Jongste 2009</td>
<td>151 children randomised FeNO group, n=75</td>
<td>Symptom group: mean age 11.6 (SD 2.6), 46 males</td>
<td>FeNO group: treatment was based on symptoms, β-agonists use, lung function and FeNO. Control group: treatment based on symptoms, β-agonists and lung function only.</td>
<td>Primary outcome: FEV1 Secondary outcomes: no. of exacerbations, MEF 50% predicted, better symptom control, less SABAs and ICS dose. Exacerbation defined by 4 parameters: oral steroid courses, and/or off-scheduled visit because of asthma symptoms over the past 4 weeks, and/or increase of asthma symptoms from a symptom score 0 or 1 to a symptom score 2 and/or decline of FEV1 (litres) &gt;10% compared with the previous visit. 1. No. of severe asthma exacerbations 2. Control of eosinophilic airway inflammation measured by the induced sputum eosinophil count 3. Exhaled nitric oxide concentrations 4. Symptom scores (0–3 for daytime and night time symptoms) 5. Total asthma quality of life scores 6. Peak flow amplitude as a proportion of the mean FEV1 7. β2-agonists 8. Changes from baseline of methacholine PC20 9. Drug use 10. Admissions for asthma 11. Severe exacerbations defined as a decrease in morning PEF to &gt;30% below baseline value on 2 consecutive days, or deterioration in symptoms needing rescue course of oral corticosteroid.</td>
<td>Children were seen at 3, 12, 21 and 30 weeks for examination, assessment of FeNO, spirometry before and after salbutamol and recording of adverse events. Study concluded at 30 week visit.</td>
</tr>
<tr>
<td>Fritsch 2006</td>
<td>52 patients entered the study. FeNO group n=22</td>
<td>Control group: mean age 12.1 (SD 2.8), 14 males</td>
<td>FeNO group: treatment was based on symptoms, β-agonists use, lung function and FeNO. Control group: treatment based on symptoms, β-agonists and lung function only.</td>
<td>Primary outcome: FEV1 Secondary outcomes: no. of exacerbations, MEF 50% predicted, better symptom control, less SABAs and ICS dose. Exacerbation defined by 4 parameters: oral steroid courses, and/or off-scheduled visit because of asthma symptoms over the past 4 weeks, and/or increase of asthma symptoms from a symptom score 0 or 1 to a symptom score 2 and/or decline of FEV1 (litres) &gt;10% compared with the previous visit. 1. No. of severe asthma exacerbations 2. Control of eosinophilic airway inflammation measured by the induced sputum eosinophil count 3. Exhaled nitric oxide concentrations 4. Symptom scores (0–3 for daytime and night time symptoms) 5. Total asthma quality of life scores 6. Peak flow amplitude as a proportion of the mean FEV1 7. β2-agonists 8. Changes from baseline of methacholine PC20 9. Drug use 10. Admissions for asthma 11. Severe exacerbations defined as a decrease in morning PEF to &gt;30% below baseline value on 2 consecutive days, or deterioration in symptoms needing rescue course of oral corticosteroid.</td>
<td>Visits were at 6, 12, 18 and 24 weeks after 4 week run-in. Study duration was for 12 months with visits at months 1, 2, 3, 4, 6, 8, 10 and 12.</td>
</tr>
<tr>
<td>Green 2002</td>
<td>74 randomised Sputum management group, n=37</td>
<td>BTP management group: median age 47, range 20–75, 21 males</td>
<td>Sputum management group: anti-inflammatory treatment was based on maintenance of sputum eosinophil count &lt;3% with a minimum dose of anti-inflammatory treatment. BTP management group: treatment decisions were based on traditional assessments of symptoms, PEF and use of β2-agonists.</td>
<td>Primary outcome: FEV1 Secondary outcomes: no. of exacerbations, MEF 50% predicted, better symptom control, less SABAs and ICS dose. Exacerbation defined by 4 parameters: oral steroid courses, and/or off-scheduled visit because of asthma symptoms over the past 4 weeks, and/or increase of asthma symptoms from a symptom score 0 or 1 to a symptom score 2 and/or decline of FEV1 (litres) &gt;10% compared with the previous visit. 1. No. of severe asthma exacerbations 2. Control of eosinophilic airway inflammation measured by the induced sputum eosinophil count 3. Exhaled nitric oxide concentrations 4. Symptom scores (0–3 for daytime and night time symptoms) 5. Total asthma quality of life scores 6. Peak flow amplitude as a proportion of the mean FEV1 7. β2-agonists 8. Changes from baseline of methacholine PC20 9. Drug use 10. Admissions for asthma 11. Severe exacerbations defined as a decrease in morning PEF to &gt;30% below baseline value on 2 consecutive days, or deterioration in symptoms needing rescue course of oral corticosteroid.</td>
<td>Study duration was for 12 months with visits at months 1, 2, 3, 4, 6, 8, 10 and 12.</td>
</tr>
<tr>
<td>Jayaram 2006</td>
<td>117 randomised Sputum strategy group, n=50</td>
<td>Clinical strategy group: mean age 43.5 (SD 13.9), 15 males</td>
<td>Sputum strategy group: dose of inhaled steroid was guided solely by induced sputum eosinophils to keep &lt;2%. Spirometry was used to identify clinical control, exacerbations and other treatment. Clinical strategy: guided by symptoms</td>
<td>Primary outcome: FEV1 with monthly visits in Phase 1 until control maintained with minimum treatment (variable duration) or at exacerbations Phase 2: 3 monthly visits or at exacerbations 1. RR reduction for the first exacerbation 2. The length of time without exacerbations 3. Type and severity of exacerbations 4. The usefulness of monitoring sputum cell counts in relation to the overall severity of asthma. Defined by the minimum dose of ICS to maintain control 5. The cumulative dose of ICS needed in Phase 2 adjusted for its duration. Exacerbation: Loss of symptomatic control requiring increased use of SABAs by 4 extra puffs per day for a minimum of 48 h, or by nocturnal symptoms, or early morning waking due to respiratory symptoms ≥2 in 1 week. Severe exacerbations were defined as requiring rescue courses of oral prednisone as defined by the investigator.</td>
<td>2 year study duration with monthly visits in Phase 1 until control maintained with minimum treatment (variable duration) or at exacerbations Phase 2: 3 monthly visits or at exacerbations</td>
</tr>
</tbody>
</table>
### Table 1

<table>
<thead>
<tr>
<th>Study</th>
<th>Sample size</th>
<th>Participant age</th>
<th>Description of intervention and control arms</th>
<th>Primary outcome and definition of exacerbation</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pinenburg 2005</td>
<td>89 children randomised, FeNO group, n=39, Symptom group, n=46</td>
<td>FeNO group: median age 11.9 (SD 2.9), 25 males. Symptom group: mean age 12.6 (SD 2.8), 30 males.</td>
<td>FeNO group: FeNO-guided ICS dosing according to predetermined algorithm. Symptom group: symptom scores influenced ICS dosing.</td>
<td>Primary outcome: cumulative steroid dose (sum of mean daily steroid doses of visits 1–5) Secondary outcomes: mean daily symptom score, mean daily number of bronchodilator doses taken, percentage of symptom-free days during the last 4 weeks of the study, number of oral prednisolone courses during the study and provocative dose of methacholine causing a 20% fall in FEV1 (PD20), FVC, FEV1, and MEF25 during final visit. Exacerbation: deterioration in symptoms requiring oral prednisolone course.</td>
<td>Study duration was 12 months with 3 monthly visits.</td>
</tr>
<tr>
<td>Shaw 2005^1^</td>
<td>118 adults were randomised, FeNO group, n=58, Control group, n=60.</td>
<td>FeNO group: median age 50 (range 20–75), 27 males. Control group: median age 52 (range 24–81), 27 males.</td>
<td>FeNO group: FeNO &gt; 26 ppb, ICS was increased. If FeNO &lt; 16 ppb or &lt; 26 ppb on 2 separate occasions, treatment was decreased. In control group treatment was doubled if JACS &gt; 1.57 and treatment halved if JACS &lt; 1.57 for 2 consecutive months. Phase 1: run-in period was for 6 weeks, after 2 weeks fluticasone 750 μg/day was commenced. Visits were every 4 weeks until optimal dose was achieved. FeNO group: adjustment of dose of ICS was based solely to keep FeNO &lt; 15 ppb at 250 ml/s. Control group: dose adjustment based on asthma symptoms, night time waking, bronchodilator use, variation in PEF rate and FEV1. Phase 2: visits every 2 months with upward adjustments made as per Phase 1 but no downward adjustments would be made from optimal dose.</td>
<td>Primary outcome: Number of exacerbations Secondary outcomes: total inhaled corticosteroid dose. Exacerbation: an increase in symptoms requiring oral steroids or antibiotics.</td>
<td>Study duration was 12 months with participants being send at baseline, 2 weeks, months 1, 2, 3, 4, 6, 8, 10 and 12.</td>
</tr>
<tr>
<td>Smith 2005^1^</td>
<td>97 patients randomised from 110 patients recruited.</td>
<td>FeNO group: n=46 in FeNO group achieved optimal dose in Phase 1 and n=28 achieved optimal dose in control group. Mean age of randomised patients was 44.8 (range 12–73), 41 males.</td>
<td>FeNO group: standard treatment modified on the basis of measurements of FeNO Control group: standard treatment based on the guidelines of NAEPP.</td>
<td>Primary outcome: frequency of exacerbation Secondary outcomes: mean daily dose of inhaled corticosteroids A minor exacerbation was defined as a daily asthma score of ≥2 on ≥2 consecutive days, whereas a major exacerbation was a daily asthma score of ≥3 on ≥2 consecutive days.</td>
<td>2 phase study, with phase 1 varying in duration (3–12 months) depending when optimal dose was deemed to have been achieved. During phase 2 (12 months) optimal dose from Phase 1 was continued and treatment stepped up if asthma control was lost.</td>
</tr>
<tr>
<td>Szefler 2008^2^</td>
<td>546 participants randomised from 780 patients screened. FeNO group n=276, Control group n=270</td>
<td>FeNO group: mean age 14.4, 146 males. Control group: mean age 14.4, 142 males.</td>
<td>FeNO group: standard treatment modified on the basis of the measurements of FeNO Control group: standard treatment based on the guidelines of NAEPP.</td>
<td>Primary outcome: no. of days with asthma symptoms. Secondary outcomes: admission to hospital, unscheduled visits to emergency departments or clinics, prednisolone courses for asthma, asthma exacerbations, days of wheeze, days of interference with activities, nights of sleep disruption, days of school or work missed, and days of interruption of guardian's activities. Exacerbation: combination of admissions to hospital, unscheduled visits and oral prednisolone.</td>
<td>The study duration was 46 weeks with visits every 6–8 weeks.</td>
</tr>
</tbody>
</table>

---

BTS, British Thoracic Society; FeNO, fractional expired nitric oxide; FEV1, forced expiratory flow in 1 s; FVC, forced vital capacity; ICS, inhaled corticosteroid; JACS, Juniper Asthma Control Score; MEF, maximal expiratory flow; NAEPP, National Asthma Education and Prevention Program; PACQLQ, Paediatric Asthma Caregiver’s Quality of Life Questionnaire; PEF, peak expiratory flow; SABA, short-acting β agonist.
inverse variance (GIV) was utilised. The rate ratios were taken from the published papers and the standard errors were calculated from CIs or p values published in the papers. Number needed to treat (NNT) was calculated from the pooled OR and its 95% CI applied to a specified baseline risk using an online calculator. If studies reported outcomes using different measurement scales, the standardised mean difference was estimated. Any heterogeneity between the study results was described and tested to see if it reached statistical significance using a $\chi^2$ test. The 95% CI estimated using a random effects model was included whenever there were concerns about statistical heterogeneity. Heterogeneity was considered significant when the p value is $<0.10$. An a priori subgroup analysis was planned for adults versus children.

RESULTS
Study selection and study characteristics
The searches identified 1550 FeNO-based studies and 2502 sputum studies (figure 1). After screening 20 and 65 papers, respectively, 6 and 3, respectively, fulfilled the inclusion criteria (figure 1) for the interventions. The nine studies (5 adult studies utilising sputum eosinophils, 6 studies utilising FeNO—2 adults, 4 children) involved 1299 participants, with 1231 completing. Of the nine studies included (table 1), six were unicentre studies and three were multicentred. Four studies were in children or adolescents, four with adult patients and one combining adolescents and adults. We classified studies into children/adolescent studies based on the mean age reported as opposed to the entry criteria. Four studies were double blind, parallel groups whereas five were single blind, parallel groups. All nine papers were published in English.

There was a degree of clinical heterogeneity between studies as summarised in table 1. Most variation related to the definition of an asthma exacerbation and the cut-off utilised for adjusting treatments. Although asthma exacerbations were an outcome measure in all papers, they differed in how they were defined, ranging from unscheduled emergency visits to defining an exacerbation using diary card data. Although there was variation in how exacerbations were defined, all included studies uniformly managed exacerbations with rescue oral steroids. Algorithms for adjustment of medications differed between studies and the cut-off values to step-up and step-down also varied across the FeNO studies (range from 2016 20 21 to 3518), and the sputum eosinophil percentages (range from 222 to 814).

Outcomes and synthesis of results
Primary (Exacerbations)
In FeNO-based adult studies (figure 2), the number of participants with exacerbations in the group with treatment adjusted according to FeNO was similar to the control group; 26 with exacerbations vs 30, respectively (p = 0.763), OR 0.85 (95% CI 0.30 to 2.43). The number of children who had exacerbations in the FeNO-based group was not significantly different in the control group (102 vs 118, respectively, p = 0.062), OR 0.75 (95% CI 0.55 to 1.01) (figure 2).

In contrast, in the sputum-based meta-analysis (figure 3) significantly fewer adults in the group that utilised sputum

Figure 2 Number of subjects who had ≥1 exacerbation over the study period (fractional exhaled nitric oxide (FeNO)).

Figure 3 Number of subject who had ≥1 exacerbation over the study period (sputum eosinophils (SpEos)).
The eosinophil count had asthma exacerbations compared with the control group (52 vs 77; p = 0.0006), OR 0.36 (95% CI 0.20 to 0.64). NNT for benefit was 6 (95% CI 4–32) over 52 weeks.

Secondary outcomes
ICS dose
For FeNO-based studies, meta-analysis of adult studies was opposite to that of paediatric studies (figure 4). Adults who had treatment adjusted according to FeNO had a significantly lower dose of ICS at the end of the study period (figure 4) than those in the control group (mean difference between groups was −450.03 µg budesonide equivalent; 95% CI −676.73 to −223.34; p < 0.0001). However, Shaw19 also reported an 11% increase in the total amount of ICS used during the study (95% CI 15% to 37%). In paediatric studies, the group who had treatment adjusted according to FeNO (figure 4) had significantly higher doses of ICS at the end of the study compared with the control group (mean difference 140.18, 95% CI 28.94 to 251.42; p = 0.014).

All three studies that utilised sputum eosinophils to adjust treatment reported no differences in doses of ICS used between groups (figure 5). The SDs for the groups were not available in Jayaram’s paper and were estimated based on the data from Green’s paper. Mean dose of ICS per person per day between groups was non-significant; weighted mean difference was 78.99, 95% CI −90.13 to 248.11; p = 0.157.

Symptom scores
Symptom scores did not differ between groups for FeNO-based studies in both adults and children (figure 6). In adults, the mean difference was −0.10, 95% CI −0.53 to 0.12; p = 0.572. In children, the mean difference was 0.13, 95% CI −0.32 to 0.57; p = 0.577. For the sputum-based studies, the two studies that reported on symptom scores also described no difference in symptoms scores between groups.14 15

Sensitivity analyses
There were insufficient data reported from the individual studies to include other secondary outcomes (forced expiratory volume in 1 s (FEV1), AHR, rescue β-agonist use, QoL) for meta-analysis. FEV1 was an outcome in all nine studies; eight studies14 15 18 19 21 described no difference between the participants who had treatment adjusted to inflammatory markers in comparison with the control group.

Results from the sensitivity analyses did not alter direction or non-significance of primary outcomes (exacerbations) but changed the final ICS dose in the paediatric studies from favouring controls to a non-significant difference between groups (see supplementary file online).

Risk of bias in individual studies
The risk of bias table (table 2) shows that four studies15 17 19 22 were considered moderate to high quality, but in all studies there were insufficient details about either allocation concealment and/or adequacy of blinding. One study14 was open labelled while another17 was single blinded.

For the FeNO-based papers, the quality of evidence using the GRADE approach surmises that of the four outcomes assessed, three were of moderate quality and one (ICS dose in children) was low quality due to one study21 being single blinded and a high final daily dose of ICS in another study20 (table 3). For sputum-based studies, GRADE assessment shows that the quality of both outcomes was low (exacerbation) and very low (ICS dose) due to the lack of blinding in one study14 and the high daily doses of ICS at the end of the study in two studies14 15 (table 4).

DISCUSSION
In this meta-analysis, we combined data from our Cochrane reviews9 10 that evaluated the efficacy of tailoring asthma interventions based on FeNO or sputum eosinophils in
comparison with controls (clinical symptoms with or without spirometry/peak flow) for asthma-related outcomes in children and adults. Based on nine studies in 1299 adults and children (1231 completed), we found that the number of adults who had an exacerbation (as defined by the author) was significantly lower in the group in which ICS was tailored based on sputum eosinophilia compared with the control group (ie, managed with the usual traditional methods, based primarily on clinical symptoms). In contrast there was no significant difference between groups when ICS was tailored based on FeNO. In children/adolescents there was a non-significant trend favouring the FeNO strategy in a number of participants with one or more exacerbations, but this was at the expense of higher levels of ICS. In adults, the FeNO-based strategy enabled a reduction in the final (but not the overall) daily dose of ICS. For both FeNO- and sputum-based strategies, there was no difference between groups for all secondary outcomes (FEV1, symptom scores, AHR and β2-agonist use).

Tailoring medications based on FeNO has been advocated in an editorial and is now relatively widely used in some countries where a rebate for its use is available. This meta-analysis has shown that the benefits of utilising an FeNO-based strategy (as opposed to a standard strategy based on clinical symptoms and simple tests such as FEV1) is at best modest and could potentially be harmful with increased ICS use in children. There was no significant difference between the two strategies in both adult and paediatric studies in the primary outcome of exacerbation when utilising FeNO. The only significant beneficial difference found between groups was the final daily dose of ICS in adults. However, this finding is limited as this was a post hoc analysis.

The primary outcome chosen was exacerbation, an important outcome as this affects the patient’s QoL and the extent to which the patient can carry out their activities of daily life. Arguably this is the most important outcome in studies on efficacy of interventions for asthma control. Our meta-analysis has shown that in contrast to the non-beneficial effect of FeNO on rate of exacerbation, tailoring treatment based on sputum eosinophils decreased the number of exacerbations experienced by this group of adults.

In contrast to the favourable data in the outcome of exacerbations that support the use of sputum to guide asthma treatments in adults, there was no significant difference between the groups for both sputum- and FeNO-based strategies in other asthma outcomes (FEV1, QoL and β2-agonist use). While exacerbations are an important outcome, arguably subjective measures of asthma control are also important. Thus, although our findings demonstrate that monitoring airway inflammation through eosinophils in induced sputum is useful in reducing exacerbations, it is debatable whether it should be universally advocated. Furthermore, sputum analysis is restricted to laboratories with specific expertise in inducing and analysing sputum. Obtaining and analysing sputum is relatively time consuming (when compared with FeNO) and is not always successful, particularly in young children. Nevertheless, use of sputum induction to guide asthma treatment is most likely to be

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Risk of bias summary of included studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chlumsky 2006</td>
<td>+</td>
</tr>
<tr>
<td>Fritsch 2006</td>
<td>?</td>
</tr>
<tr>
<td>Green 2002</td>
<td>+</td>
</tr>
<tr>
<td>Jayaram 2006</td>
<td>+</td>
</tr>
<tr>
<td>Pijnenburg 2005</td>
<td>?</td>
</tr>
<tr>
<td>Szefler 2008</td>
<td>+</td>
</tr>
</tbody>
</table>
beneficial in adults with severe asthma and those with frequent exacerbations.

The FeNO-based studies need to be considered in light of several issues. First, none of the six included studies utilising FeNO considered presence or severity of atopy in their algorithm of management, although some but not all subjects were atopic. Raised FeNO in children has been associated with atopy with or without management, although some but not all subjects were atopic. FeNO considered presence or severity of atopy in their algorithm of several issues. First, none of the six included studies utilising FeNO analyses as reported in risk of bias table.

Studies reported technical difficulties with FeNO analyses as reported in risk of bias table. One study (deJongste 2008) design was open label which may have introduced bias. Medication increased prior to commencement of study.

Participants 197 (2 studies) moderate 1

Number of subjects who had one or more exacerbations over the study period in children and adolescents Follow-up: 26-52 weeks

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Illustrative comparative risks* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>No of Participants (studies)</th>
<th>Quality of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of subjects who had one or more exacerbations over the study period in adults Follow-up: 52 weeks</td>
<td>30 per 100 27 per 100 (12 to 51)</td>
<td>OR 0.85 (0.3 to 2.43)</td>
<td>197 (2 studies)</td>
<td>moderate 1</td>
<td></td>
</tr>
<tr>
<td>Number of subjects who had one or more exacerbations over the study period in children and adolescents Follow-up: 26-52 weeks</td>
<td>36 per 100 30 per 100 (24 to 36)</td>
<td>OR 0.75 (0.55 to 1.01)</td>
<td>782 (3 studies)</td>
<td>moderate 2,3,4</td>
<td></td>
</tr>
<tr>
<td>ICS dose at final visit in adults mcg/day Follow-up: 52 weeks</td>
<td>The mean ICS dose at final visit in adults in the control groups was 1088 mcg/day (budesonide equivalent) 450 lower (677 to 223 lower)</td>
<td>The mean ICS dose at final visit in adults in the intervention groups was 777 (3 studies)</td>
<td>197 (2 studies)</td>
<td>moderate 5</td>
<td></td>
</tr>
<tr>
<td>ICS dose at final visit in children and adolescents mcg/day Follow-up: 26-52 weeks</td>
<td>The mean ICS dose at final visit in children and adolescents in the control groups was 804 mcg/day (budesonide equivalent) 140 higher (29 to 251 higher)</td>
<td>The mean ICS dose at final visit in children and adolescents in the intervention groups was 197 (2 studies)</td>
<td>782 (3 studies)</td>
<td>moderate 2,3,4</td>
<td></td>
</tr>
</tbody>
</table>

GRADE Working Group grades of evidence.

High quality: further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: we are very uncertain about the estimate.

*The basis for the assumed risk (eg, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

1 CIs are wide and include clinically important benefit and harm.
2 One study (deJongste 2008) design was open label which may have introduced bias.
3 Studies reported technical difficulties with FeNO analyses as reported in risk of bias table.
4 Medication increased prior to commencement of study.
5 In one study the overall dose of ICS was higher with FeNO-based interventions even though the final ICS dose was lower.
6 One study presented in these results was single blinded with the intervention arm analysing FeNO only.
7 Final ICS doses were quite varied, with one study having particularly high doses.

FeNO, fractional expired nitric oxide; ICS, inhaled corticosteroid.
a monitoring tool adds not only cost but also another layer of complexity in asthma care. Analysers were only approved by the US Food and Drug Administration for clinical monitoring of anti-inflammatory treatment in 2005. As reported in the risk of bias table (table 2), accurate FeNO measurements at each visit could not be obtained, due either to a faulty analyser or to technical issues. Also, many aspects need to be considered when analysing FeNO; this includes the timing of spirometry (transiently reduces FeNO), food and beverage, circadian rhythm, smoking history, ambient nitric oxide and exercise.

**Limitations of the review**

This systematic review is limited to nine studies with 1231 subjects completing the trials. While the studies share some common issues, there are also significant differences, notably the definition of asthma exacerbation, how the decision to prescribe oral steroids was made, the different cut-off levels for FeNO and sputum eosinophils, asthma exacerbation, how the decision to prescribe oral steroids was made, and include outcomes of exacerbations, subjective measures (such as scores for asthma control and QoL) as well as objective measures (FEV1, etc.). It is likely that a clear algorithm based on outcomes rather than a single cut-off is required. Analysis of possible mechanisms.

**Conclusions**

The studies included in this review highlight the difficulties involved in tailoring the dose of ICS based on inflammatory markers (FeNO and sputum eosinophils), instead of primarily on clinical symptoms. Tailoring of asthma treatment based on sputum is effective in decreasing asthma exacerbations in adults. However, tailoring of asthma treatment based on FeNO levels has not been shown to be effective in improving asthma outcomes in children and adults. At present, despite their popularity, there is insufficient evidence to advocate their use in routine clinical practice.

Further randomised controlled trials in both adults and children are required. A priori pragmatic issues of clinical practice such as high versus low doses of ICS and, to a lesser extent, eosinophilic versus non-eosinophilic asthma should be considered with costs analysis for each subgroup. Future randomised controlled trials should preferably be parallel multicentre studies and include outcomes of exacerbations, subjective measures (such as scores for asthma control and QoL) as well as objective measures (FEV1, etc.). It is likely that a clear algorithm based on outcomes rather than a single cut-off is required. Analysis of costs and possible adverse events of inhaled and oral corticosteroids would also provide additional important information.

**Funding**

Australian Cochrane Airways Group and Royal Children’s Hospital Foundation. AC is supported by an NHMRC Practitioner Fellowship (grant no. 545216).

**Competing interests**

None.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**References**


